Table 4.

Summary of Fc enhanced hu3F8

	hu3F8-IgG1	hu3F8-IgG1n	hu3F8-IgG1-DEL	hu3F8-IgG1n-DEL
KD (CD16A-158F)*	1	4	16	37
KD (CD16A-158V)*	3	11	25	63
KD (CD32A-131R)**	1.0	0.5	1.4	0.3
KD (CD32A-131H)**	1.3	0.6	1.3	0.3
A:I FcR ratioˆ	9	35	18	165
ADCC(CD16A-158V)	1	26	35	84
ADCC(CD32A-131H)	1.0	0.1	0.9	0.1
CMC	1.0	0.6	0.4	≤0.05
t1/2	17	22	31	2
Cmax	55	69	84	103
AUC	1171	902	2029	293
In vivo antitumor effect	+	+++	+	+

^*Normalized to K_D of hu3F8-IgG1 on CD16A-158F.

^**Normalized to K_D of hu3F8-IgG1 on CD32A-131R.

^ˆA:I = Activating: inhibitory = (relative K_A on CD16-158V)/(relative K_A on CD32B).